Xiaoyu Yan possesses extensive expertise in pharmacokinetics, pharmacodynamics, and computational oncology. Yan leads a dynamic and diverse team specialising in model-informed drug discovery and development, with a particular emphasis on large molecules. His pioneering work includes the development of advanced modelling and simulation platforms aimed at addressing challenges in drug development, translation, and clinical application.

Yan has substantial experience collaborating with clinicians, regulatory agencies, and the pharmaceutical industry, enabling him to make significant contributions to pharmaceutical sciences and computational pharmacology. He has authored over 50 peer-reviewed publications. During his time in the industry, Yan supported multiple therapeutic areas, including oncology, immunology, cardiovascular, and neuroscience. He contributed to the BLA (sBLA) and NDA (sNDA) submissions of several drugs, such as DARZALEX (daratumumab), SIMPONI (golimumab), NUCYNTA (tapentadol), XARELTO (rivaroxaban), SPRAVATO (esketamine), and LIBTAYO (cemiplimab).